ABSTRACT
Increased levels of circulating cell-free DNA (cf-DNA) are associated with and predict poor health outcomes. However, its predictive ability for mortality in population-based samples remains understudied. We analysed the capability of cf-DNA to predict all-cause mortality and assessed whether it adds predictive value on top of the other risk factors in the Health 2000 survey (n = 1,257, 46-76 years of age, 15-years-follow-up, 18% deceased). When analysed in a multivariate model with the other factors that independently predicted mortality in the sample (age, gender, self-rated health, smoking and plasma levels of glucose and adiponectin), increases in cf-DNA levels were associated with increased risk of mortality (hazard ratio [HR] for 0.1 µg increase in cf-DNA: 1.017, 95% confidence interval [CI] 1.008-1.026, p = 0.0003). Inclusion of cf-DNA in the model improved the model fit and discrimination. Stratifying the analysis by cardiovascular disease (CVD) status indicated that cf-DNA predicted mortality equally well in individuals with (HR 1.018, 95% CI 1.008-1.026, p = 0.002) and without (HR 1.018, 95% CI 1.001-1.035, p = 0.033) CVD. In conclusion, our study indicates that cf-DNA level predicts mortality in middle-aged and older individuals, also among those with established CVD, and adds significant value to mortality prediction. Our results thus underscore the role of cf-DNA as a viable marker of health.
Subject(s)
Cardiovascular Diseases/mortality , Cause of Death , DNA/blood , Age Factors , Aged , Biomarkers/blood , Female , Health Surveys , Humans , Male , Middle Aged , Predictive Value of Tests , Risk FactorsABSTRACT
BACKGROUND AND AIMS: Obese subjects have elevated leptin levels, which have been associated with increased risk of cardiovascular events. Because leptin has direct cellular effects on various tissues, we tested the hypothesis that leptin levels are associated with cardiac structure or function in patients with coronary artery disease (CAD). METHODS AND RESULTS: The study population consisted of 1 601 CAD patients, of whom 42% had type 2 diabetes mellitus. Plasma leptin was measured in fasted state and an echocardiography performed. Leptin levels were not related to LV dimensions or LV ejection fraction (NS for all), but higher leptin levels were associated with elevated E/E' (9.43 vs. 11.94 in the lowest and the highest leptin quartile, respectively; p=0.018 for trend). Correspondingly, a decreasing trend was observed in E/A (1.15 vs. 1.06; p=0.037). These associations were independent of obesity and other relevant confounding variables. CONCLUSION: We conclude that elevated plasma leptin levels are associated with impaired left ventricular diastolic function in patients with CAD independently of obesity and other confounding variables. Leptin may be one of the mechanistic links explaining the development of congestive heart failure in obese subjects.
Subject(s)
Coronary Artery Disease/blood , Heart Failure/blood , Leptin/blood , Obesity/blood , Aged , Coronary Artery Disease/etiology , Coronary Artery Disease/physiopathology , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/pathology , Diastole/physiology , Echocardiography , Female , Heart Failure/physiopathology , Humans , Male , Middle Aged , Obesity/complications , Obesity/pathology , Risk Factors , Ventricular Dysfunction, Left/blood , Ventricular Dysfunction, Left/etiology , Ventricular Dysfunction, Left/physiopathologyABSTRACT
BACKGROUND AND AIMS: Vitamin D deficiency has been associated with increased risk for cardiovascular (CV) disease, but the possible effects of Vitamin D on cardiac structure and function are not well characterized. METHODS AND RESULTS: The correlation between 25-hydroxyvitamin D levels and metabolic and cardiac echocardiographic parameters was studied in ARTEMIS study population including 831diabetic and 659 non-diabetic patients with stable coronary artery disease (CAD). Low levels of Vitamin D were associated with high BMI (p < 0.001), high total and LDL cholesterol and triglyceride levels (p < 0.001 for all) in both diabetics and non-diabetics. Among non-diabetic patients, low Vitamin D was also associated independently with elevated systolic and diastolic blood pressure (p < 0.005). Low Vitamin D levels were independently associated with reduced left ventricular (LV) ejection fraction (p < 0.005) and increased left atrial diameter (p < 0.03) measured by cardiac ultrasound by 2-dimensional echo. In the non-diabetic group, low Vitamin D levels were associated with impaired LV filling (high E/E') (p < 0.03) and low E/A mitral flow pattern measured by Doppler echocardiography (p < 0.05). Among diabetics, low Vitamin D levels were also related to increased LV end-systolic diameter (p < 0.05) and right ventricular diameter (p < 0.005). The association between LV diastolic filling (E/E') and Vitamin D levels was significant (p < 0.01) after adjustment for the commonly recognized risk factors of diastolic dysfunction in linear regression analysis. CONCLUSIONS: Low Vitamin D is associated with several major cardiovascular risk factors and cardiac structural changes including impaired systolic and diastolic function, which together may explain the association of low Vitamin D to worse cardiovascular outcome.
Subject(s)
25-Hydroxyvitamin D 2/blood , Calcifediol/blood , Cardiovascular Diseases/etiology , Coronary Artery Disease/physiopathology , Heart/physiopathology , Nutritional Status , Vitamin D Deficiency/physiopathology , Adult , Aged , Aged, 80 and over , Cardiovascular Diseases/diagnostic imaging , Cardiovascular Diseases/epidemiology , Cohort Studies , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/etiology , Coronary Artery Disease/pathology , Echocardiography, Doppler , Female , Finland/epidemiology , Heart Atria/diagnostic imaging , Heart Atria/pathology , Heart Atria/physiopathology , Heart Ventricles/diagnostic imaging , Heart Ventricles/pathology , Heart Ventricles/physiopathology , Humans , Male , Middle Aged , Organ Size , Prevalence , Risk Factors , Stroke Volume , Ventricular Dysfunction, Left/diagnostic imaging , Ventricular Dysfunction, Left/etiology , Ventricular Dysfunction, Left/pathology , Ventricular Dysfunction, Left/physiopathology , Vitamin D Deficiency/blood , Vitamin D Deficiency/pathologyABSTRACT
BACKGROUND/OBJECTIVES: The association of dietary sodium and cardiovascular disease (CVD), as well as the reduction of sodium intake in the prevention of CVD, has been under debate. To study whether sodium consumption has a role as a risk factor for fatal and non-fatal CVD. SUBJECTS/METHODS: A well-defined population-based cohort of 1045 subjects collected between 1991 and 1993 (mean age 51.4 years) was used with approximately 19 years' follow-up. At the baseline, 716 subjects filled in a 1-week food follow-up diary, which was used to calculate the daily sodium intake (mg/1000 kcal). RESULTS: The baseline sodium intake correlated significantly with age (rs=0.117, P=0.002), BMI (rs=0.216, P=0.000), waist circumference (rs=0.268, P=0.000), smoking (rs=0.144, P=0.000), alcohol consumption (rs=0.111, P=0.003), systolic blood pressure (rs=0.106, P=0.005) and low-density lipoprotein (LDL) cholesterol (rs=0.081, P=0.033). Those who had cardiovascular events in the follow-up consumed more sodium at the baseline (mean 2010.4 mg/1000 kcal/day, s.d. 435.2, n=101) compared with the subjects without events (mean 1849.9 mg/1000 kcal/day, s.d. 361.2, n=589; t-test; P=0.001). The incidence of cardiovascular events was greater in the highest quartile (22.1%) than in the lower quartiles (first 11.0%, second 9.9% and third 15.6%; X(2); P=0.005). Cox regression analysis showed that sodium intake as a continuous variable predicts CVD events (P=0.031) independently when age, sex, smoking, alcohol consumption, systolic blood pressure, LDL cholesterol and waist circumference were added as covariates. This predictive role is seen especially in the group of subjects on hypertensive medication (P=0.001). CONCLUSIONS: Dietary sodium intake is a significant independent predictor of cardiovascular events in the study population.
Subject(s)
Cardiovascular Diseases/epidemiology , Sodium, Dietary/analysis , Adult , Age Factors , Aged , Alcohol Drinking/adverse effects , Antihypertensive Agents/therapeutic use , Blood Pressure , Body Mass Index , Cardiovascular Diseases/etiology , Cholesterol, LDL/blood , Diet Records , Female , Follow-Up Studies , Humans , Incidence , Male , Middle Aged , Proportional Hazards Models , Risk Factors , Sex Factors , Smoking/adverse effects , Sodium, Dietary/adverse effects , Waist CircumferenceABSTRACT
The aim of our investigation was to find out if ghrelin concentrations or polymorphisms predict the future risk for cardiovascular diseases and cancer in a population-based cohort initiated in 1991 (491 hypertensive and 513 control subjects). Total mortality and hospital events were followed up for 19 years. Fasting total ghrelin concentrations were determined and Arg51Gln, Leu72Met and -501 A > C polymorphisms identified. Cox regression analysis was performed. The mean value in the control cohort was 674 pg/ml whereas in the hypertensive cohort it was 661 pg/ml. The associations found suggest that in the controls the highest ghrelin quartile protected from CHD (coronary heart disease). The results were significant without or with adjustments for age, sex, smoking, systolic blood pressure and LDL cholesterol, BMI, type 2 diabetes or QUICK index. C/C variant of the promoter associated with the prevention of IHD (ischemic heart disease) in the hypertensive group (p<0.05). The controls with the Leu72Leu genotype had less cancer (p<0.05). In conclusion, high plasma ghrelin concentration was related to protection from CHD and Leu72Leu genotype to prevention of cancer in healthy adults during the 19 years follow-up. C/C promoter protects from IHD in the hypertensive subjects.
Subject(s)
Coronary Disease , Ghrelin , Hypertension , Neoplasm Proteins , Neoplasms , Polymorphism, Genetic , Adult , Amino Acid Substitution , Coronary Disease/blood , Coronary Disease/genetics , Coronary Disease/pathology , Female , Follow-Up Studies , Ghrelin/blood , Ghrelin/genetics , Humans , Hypertension/blood , Hypertension/genetics , Hypertension/pathology , Male , Middle Aged , Mutation, Missense , Neoplasm Proteins/blood , Neoplasm Proteins/genetics , Neoplasms/blood , Neoplasms/genetics , Neoplasms/pathologyABSTRACT
The roles of ghrelin, a peptide hormone that has a role in regulating food intake and energy homeostasis, in the cardiovascular system have not yet been unambiguously established. We evaluated the association between plasma ghrelin concentrations and -501A>C single-nucleotide polymorphism (SNP) in the ghrelin gene 5' flanking area and echocardiographic measurements in 1037 middle-aged subjects. Left ventricular mass index (LVMI) was calculated according to Devereux's method. The ambulatory blood pressure (BP) was recorded using the fully automatic SpaceLabs 90207 oscillometric unit. Results suggested that plasma ghrelin was not related to mean ambulatory BP values. However, the highest plasma ghrelin tertile was associated with increased intraventricular septum (P=0.043) and posterior ventricular wall (P=0.002) thicknesses as well as left ventricular mass (P=0.05). After adjustment for age, sex, body mass index and systolic BP, the association persisted between ghrelin tertiles and intraventricular septum (P=0.05) and posterior ventricular wall (P=0.001) thicknesses. The SNP -501A>C polymorphism was associated with LVMI after adjustments for age, sex and systolic BP. In conclusion, ghrelin and its promoter variant are associated with cardiac hypertrophy indexes independent of BP. Positive correlation between ghrelin levels and increased wall thickness parameters may reflect compensatory up-regulation of ghrelin concentrations or direct effects of ghrelin on myocardium. The effects of the SNP seem not to be mediated through its effects on ghrelin plasma levels.
Subject(s)
Ghrelin/genetics , Hypertrophy, Left Ventricular/genetics , Polymorphism, Single Nucleotide , Promoter Regions, Genetic , Blood Pressure , Echocardiography , Female , Ghrelin/blood , Human Growth Hormone/physiology , Humans , Male , Middle AgedABSTRACT
OBJECTIVE: To investigate how inflammation and metabolic syndrome (MetS) are associated with adipokine levels in patients with inflammatory arthritis. METHODS: Fifty-four female patients with arthritis were enrolled in the study. Twenty (37%) of these patients had MetS, which was diagnosed according to the definition of the International Diabetes Federation (IDF). Interleukin (IL)-6 and four adipokines (resistin, leptin, adiponectin, and adipsin) were determined by immunoassay. Healthy women with body mass index (BMI) between 22 and 25 kg/m(2) served as controls. RESULTS: The patients with arthritis had higher levels of resistin than the healthy controls. This difference was clear in patients without MetS (17.4 in patients vs. 10.8 ng/mL in controls, p < 0.001), and even higher resistin levels were found in the patients with MetS (20.7 ng/mL; p < 0.001 vs. healthy controls; and p = 0.095 vs. patients without MetS). In the patients with arthritis and MetS, resistin correlated positively with IL-6 (Pearson's r = 0.5, p = 0.03). Leptin levels were increased in arthritis patients with MetS as compared to healthy controls, but not in patients without MetS. The statistically significant difference between patients with MetS and controls remained when leptin was adjusted with BMI. Accordingly, adiponectin levels were lower in patients with MetS than in healthy controls (p < 0.05). Leptin, adiponectin, and adipsin did not correlate with the inflammatory cytokine IL-6 or with C-reactive protein (CRP). CONCLUSIONS: The results show that high resistin levels are associated with arthritis independently of MetS, whereas leptin is increased only in arthritis patients with MetS.
Subject(s)
Arthritis/physiopathology , Inflammation/physiopathology , Leptin/physiology , Metabolic Syndrome/physiopathology , Resistin/physiology , Adiponectin/blood , Adult , Arthritis/blood , Arthritis/epidemiology , Biomarkers/blood , Body Mass Index , C-Reactive Protein/metabolism , Case-Control Studies , Comorbidity , Complement Factor D/metabolism , Female , Humans , Inflammation/blood , Inflammation/epidemiology , Leptin/blood , Metabolic Syndrome/blood , Metabolic Syndrome/epidemiology , Middle Aged , Resistin/bloodABSTRACT
BACKGROUND: Ghrelin is a peptide hormone which has been shown to associate with obesity, hypertension and Type 2 diabetes (T2DM) in cross-sectional studies. AIM: To study whether total ghrelin levels have predictive value for the incidence of impaired glucose regulation (IGR) or T2DM. SUBJECTS AND METHODS: The subjects of this prospective follow-up study (no.=201) belonged to a population-based cohort collected in Northern Finland. Oral glucose tolerance tests (OGTT) and measurements of fasting serum total ghrelin, lipids, blood pressure and body mass index were performed at the beginning and at the end of the study. The mean follow-up time was 5.1 yr. The subjects had normal glucose tolerance (NGT) at the beginning of the study. RESULTS: T2DM developed in 6 (3%), impaired fasting glucose (IFG) in 6 (3%) and impaired glucose tolerance (IGT) in 35 (17.4%) subjects. The baseline ghrelin concentrations did not differ between the two studied groups: median fasting serum total ghrelin concentration was 733 pg/ml (25th-75th percentiles: 571-961 pg/ml) among those who maintained NGT, and 661 pg/ml (25th-75th percentiles: 527- 878 pg/ml) among those who developed IGR (IFG and/or IGT) or T2DM (p=0.421). The baseline ghrelin concentrations did not explain the changes in the 0-h or 2-h blood glucose concentrations in regression models. CONCLUSIONS: Our findings suggest that fasting serum total ghrelin levels measured at one time point might not have predictive value for the development of abnormalities in glucose tolerance.
Subject(s)
Diabetes Mellitus, Type 2/etiology , Ghrelin/blood , Glucose Intolerance/etiology , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/blood , Fasting , Female , Follow-Up Studies , Humans , Lipids/blood , Male , Middle Aged , Prospective StudiesABSTRACT
The objective of this study was to analyse the relationship between the ambulatory blood pressure (ABP) measurement and plasma adiponectin levels in a population-based cohort. Non-hypertensive, non-diabetics from the Oulu Project Elucidating Risk of Atherosclerosis cohort aged 40-60 years with ABP measurement available in 226 men and 236 women were analysed. ABP was recorded using the fully automatic SpaceLabs 90207 oscillometric unit. Plasma adiponectin concentrations were assayed using the enzyme-linked immunosorbent assay method. Without adjustment the highest plasma adiponectin tertile was associated with the lowest ABP and office BP measurements (P from 0.025 to P<0.001, respectively). Only the association of plasma adiponectin concentration with systolic ABP was independent of other conventional risk factors (age, body mass index (BMI), waist, gender, insulin sensitivity index, smoking and alcohol consumption) for hypertension (P=0.017). No association was observed between systolic dipping pattern and adiponectin level. The plasma high adiponectin concentration is independently associated with low daytime systolic ABP value. The mechanisms may include effects on endothelial function and the sympathetic nervous system.
Subject(s)
Blood Pressure/physiology , Circadian Rhythm/physiology , Hypertension/epidemiology , Hypertension/metabolism , Adiponectin/blood , Adult , Blood Pressure Monitoring, Ambulatory , Case-Control Studies , Cohort Studies , Female , Humans , Hypertension/diagnosis , Male , Middle Aged , Risk Factors , Sex Distribution , Sympathetic Nervous System/physiologyABSTRACT
A non-dipping pattern in ambulatory blood pressure monitoring (ABPM) increases the risk of cardiovascular disease. The association between renal function and the dipping pattern has not been studied in a random middle-aged population. This is a cross-sectional population-based study of 226 males and 234 females aged 40 to 62 years. Renal function was assessed with estimated glomerular filtration rate (eGFR). Non-dipping status was defined as a reduction of <10% between the daytime and the nighttime systolic BP. Non-dippers represented 18.7% of the study population. Their mean eGFR was 79.1 (s.d. 15.7) ml min(-1) per 1.73 m(2) as compared with a mean eGFR of 84.1 (s.d. 16.2) ml min(-1) per 1.73 m(2) in dippers (P=0.005); this difference remained significant after adjustments. Subjects in the lowest and in the middle eGFR tertiles had an independently increased risk of non-dipping in comparison with those in the highest eGFR tertile (odd ratios (OR), 2.34 (95% confidence interval (CI), 1.18 to 4.63) and OR, 2.01 (95% CI, 1.06 to 3.83), respectively). This study showed that even a minor deterioration in renal function is associated with increased risk of non-dipping pattern in ABPM in a random middle-aged population.
Subject(s)
Blood Pressure Monitoring, Ambulatory , Blood Pressure/physiology , Glomerular Filtration Rate , Hypertension, Renal/diagnosis , Hypertension, Renal/epidemiology , Adult , Alcohol Drinking/epidemiology , Circadian Rhythm/physiology , Creatinine/blood , Cross-Sectional Studies , Female , Humans , Hypertension, Renal/physiopathology , Logistic Models , Male , Middle Aged , Risk FactorsABSTRACT
Roux-en-Y gastric bypass leads to a marked improvement of glucose control. The mechanisms are only partly known. Gastrointestinal hormones may play a role. Of these, glucagon-like peptide 1 and peptide YY have been most consistently associated with the beneficial effects of gastric bypass on glucose metabolism and weight. In this paper, a short review of the topic is presented and a suggestion of the improvement of glucose metabolism is made based on the current published work.
Subject(s)
Gastric Bypass/methods , Glucose/metabolism , Animals , Gastric Bypass/trends , Gastrointestinal Hormones/metabolism , Glycemic Index/physiology , Humans , Obesity/metabolism , Obesity/physiopathology , Obesity/surgery , Weight Loss/physiologyABSTRACT
BACKGROUND: Involvement of low density lipoprotein (LDL) immune complexes (ICs) in atherogenesis has been proposed. Human FcgammaRIIa receptor (CD32) plays a crucial role in the phagocytosis of IgG(2) ICs and a functional point mutation 131His/Arg diminishes IgG(2) binding to the receptor. STUDY DESIGN: We examined FcgammaRIIa-131His/Arg polymorphism, IgG(2) antibody titres to oxidized low-density lipoprotein (OxLDL) and Streptococcus pneumoniae cell wall polysaccharide (CWPS) and subclinical atherosclerosis in a large cohort of Finnish subjects (n = 1041). RESULTS: Non-smoking subjects with homozygous 131His/His genotype had more premature atherosclerosis (P = 0.004) and higher IgG(2) to bacterial CWPS (P = 0.002) compared with other genotypes. Smoking subjects had significantly higher intima-media thickness (IMT) than that of non-smokers (P < 0.001) and genotype-dependent associations were indistinct. There was no association between FcgammaRIIa genotype and antibody titres to OxLDL. CONCLUSIONS: Our data demonstrate that FcgammaRIIa 131His/Arg polymorphism is associated with subclinical atherosclerosis in non-smoking subjects. Furthermore, FcgammaRIIa genotype is associated with IgG(2) titres to bacterial CWPS, but not to OxLDL. These data propose possible involvement of FcgammaRIIa receptor in atherogenesis.
Subject(s)
Atherosclerosis/genetics , Immunoglobulin G/genetics , Lipoproteins, LDL/genetics , Pneumococcal Infections/genetics , Receptors, IgG/genetics , Atherosclerosis/immunology , Female , Genetic Predisposition to Disease , Genotype , Humans , Immunoglobulin G/immunology , Lipoproteins, LDL/immunology , Male , Middle Aged , Pneumococcal Infections/immunology , Polymorphism, Genetic , Receptors, IgG/immunologyABSTRACT
OBJECTIVE: In the general population, leptin has been associated with atherosclerosis and has been shown to interfere with lipoprotein profiles. Patients with chronic renal failure are at increased risk of cardiovascular disease and display alterations in both lipoprotein and leptin levels. The aim of this study was to investigate the relationship between leptin and the lipoprotein profile in non-dialyzed patients with chronic kidney disease (CKD). MATERIAL AND METHODS: Leptin and lipid and lipoprotein concentrations were studied in 73 CKD patients and in 68 healthy controls in a cross-sectional case-control design. RESULTS: The mean leptin levels were increased in the CKD patients (24.0 (SD 37.1) ng/mL) compared to those in controls (9.0 (SD 8.5) ng/mL) (p = 0.008). Also, the ratio between leptin levels and body mass index (leptin/BMI) was increased in CKD patients (mean 0.80 (SD 1.03)) compared to that in controls (0.31 (SD 0.24)) (p = 0.001). In linear regression analysis, leptin independently predicted total cholesterol and triglycerides in CKD patients (p = 0.010 and p = 0.001, respectively) and ratio between total and HDL cholesterol (Chol/HDL) in controls (p = 0.024). Furthermore, in CKD patients, the leptin/BMI predicted the variation in total cholesterol and triglycerides (p = 0.010 and p = 0.002, respectively). CONCLUSIONS: Leptin concentrations and leptin/BMI were elevated in CKD patients compared to those in controls. Leptin levels in both study groups, and leptin/BMI in the CKD group, were associated with atherogenic lipid profiles, which may contribute to the elevated cardiovascular risk that has been linked to hyperleptinaemia.
Subject(s)
Kidney Failure, Chronic/blood , Leptin/blood , Lipids/blood , Adolescent , Adult , Aged , Case-Control Studies , Cross-Sectional Studies , Female , Humans , Lipoproteins/blood , Male , Middle AgedABSTRACT
BACKGROUND AND AIMS: Most gene expression studies examining the effect of obesity and weight loss have been performed using adipose tissue. However, the liver also plays a central role in maintaining energy balance. We wanted to study the effects of a hypocaloric diet on overall hepatic gene expression and metabolic risk factors. METHODS AND RESULTS: The study subjects were middle-aged, obese women. The diet intervention subjects (n=12) were on a hypocaloric, low-fat diet for 8 weeks with a daily energy intake of 5.0 MJ (1200 kcal), while the control subjects (n=19) maintained their weight. Liver biopsies were taken at the end of the diet period during a gallbladder operation. Hepatic gene expression was analyzed using microarrays by comparing the gene expression profiles from four subjects per group. A global decrease in gene expression was observed with 142 down-regulated genes and only one up-regulated gene in the diet intervention group. The diet resulted in a mean weight loss of 5% of body weight. Triglyceride and fasting insulin concentrations decreased significantly after the diet. CONCLUSIONS: The global decrease in hepatic gene expression was unexpected but the results are interesting, since they included several genes not previously linked to weight reduction. However, since the comparison was made only after the weight reduction, other factors in addition to weight loss may also have been involved in the differences in gene expression between the groups. The decrease in triglyceride and fasting plasma insulin concentrations is in accordance with results from previous weight-loss studies.
Subject(s)
Diet, Fat-Restricted , Gene Expression , Liver/metabolism , Obesity/blood , Obesity/diet therapy , Aged , Down-Regulation , Fasting/blood , Female , Humans , Insulin/blood , Microarray Analysis , Middle Aged , Obesity/physiopathology , Oligonucleotide Array Sequence Analysis , Risk Factors , Triglycerides/blood , Up-Regulation , Weight LossABSTRACT
OBJECTIVES: Apolipoprotein (apo) E phenotype has been associated with inflammation markers. The determinants of these associations and the relationship between novel inflammation marker, resistin, and apoE phenotype are studied here. METHODS AND RESULTS: Middle-aged subjects of the population- based cohort (n = 526) of the OPERA- study were studied. Intima-media thickness (IMT) was measured with carotid ultrasound. The results suggest that, apoE phenotype was a significant independent predictive factor for resistin (p < 0.01) and hsCRP (p < 0.01) levels. The association of ApoE phenotype with hsCRP was seen among the subjects with the normal renal function (p = 0.005). ApoE4 was associated (p < 0.01) with the lowest hsCRP in the lowest IMT quartile while it's relation with the highest resistin levels was evident in the highest IMT quartile. CONCLUSIONS: ApoE phenotype is an independent determinant of plasma resistin and hsCRP levels. The extent of atherosclerosis and renal function seem to modify the effects of apoE phenotype on inflammatory parameters.
Subject(s)
Apolipoproteins E/metabolism , Biomarkers/blood , Phenotype , Resistin/blood , Adult , Atherosclerosis/metabolism , Atherosclerosis/pathology , C-Reactive Protein/metabolism , Female , Humans , Male , Middle Aged , Tunica Intima/anatomy & histology , Tunica Intima/diagnostic imaging , Tunica Media/anatomy & histology , Tunica Media/diagnostic imaging , UltrasonographyABSTRACT
Gene expression studies have demonstrated the altered expression level of placental angiogenesis related genes in severe pre-eclampsia (PE). In cord compression, the transportation of oxygen from the placenta to the fetus is blocked, and it is speculated that during blockade the originally hypoxic placenta may become hyperoxic. We compared the placental gene expression profiles of one pre-eclamptic patient with cord compression (the index patient) to the profiles of patients with PE and those of normal pregnancy controls (including one woman with cord compression). The gene expression of the cord compression PE patient resembled that observed in the normal pregnancies. We hypothesize that umbilical blockade may in a short period of time lead to placental hyperoxia, which in turn has an effect on angiogenic gene expression profile.
Subject(s)
Neovascularization, Physiologic/genetics , Placenta/metabolism , Pre-Eclampsia/genetics , Pregnancy Complications, Hematologic/pathology , Umbilical Cord/pathology , Adult , Case-Control Studies , Female , Gene Expression Regulation , Humans , Nuchal Cord/genetics , Placental Circulation/genetics , Placental Circulation/physiology , Pregnancy , Pregnancy Complications, Hematologic/geneticsABSTRACT
UNLABELLED: Low adiponectin levels have been associated with high body mass index, low insulin sensitivity, and diabetes. OBJECTIVE: To assess the relationships between changes in serum adiponectin concentration and adiposity, glucose, and insulin in response to long-term overfeeding in identical twins and to calculate the twin resemblance in serum adiponectin concentrations. SUBJECTS AND DESIGN: Twenty-four sedentary young men [mean (+/-SD) age, 21+/-2 yr] who constituted 12 pairs of healthy identical twins were studied for metabolic and adiponectin changes in response to overfeeding. INTERVENTION: Subjects were overfed by 84,000 kcal over a 100-day period. OUTCOME MEASURES: The overfeeding study provides an opportunity to examine the relationships between adiponectin and changes in body weight, adiposity, plasma glucose and insulin. RESULTS: Serum adiponectin concentration correlated positively with body weight (r= 0.41, p=0.05) at baseline but not with indicators of adiposity or with visceral fat. No relationship existed between baseline adiponectin concentration and body weight or adiposity gains with overfeeding. However, serum adiponectin decreased significantly by -2.35+/-0.48 microg/ml (p=0.001) in response to overfeeding. Baseline adiponectin levels correlated negatively with changes in plasma fasting glucose levels (r=-0.53, p=0.01) and homeostasis model assessment index (r=-0.41, p=0.05), independently of fat mass. The intrapair coefficient for twin resemblance (r=0.75, p=0.001) strongly suggests that baseline serum adiponectin concentration is a familial trait. CONCLUSIONS: These data provide evidence that adiponectin concentration is a familial trait in normal-weight individuals, that it decreases when challenged by positive energy balance, and that its overfeeding-induced variations are correlated with glucose and insulin levels.
Subject(s)
Insulin/metabolism , Overnutrition/metabolism , Twins, Monozygotic , Adiponectin/blood , Adult , Blood Glucose/metabolism , Humans , Insulin/blood , Insulin Resistance , Leptin/blood , Male , Overnutrition/blood , Twins, Monozygotic/blood , Twins, Monozygotic/metabolismABSTRACT
OBJECTIVES: Neuropeptide Y (NPY) plays a central in energy homeostasis and potentially in the development of obesity-related comorbidities, like type II diabetes. As the PreproNPY Leu7Pro polymorphism probably changes the intracellular processing of the synthesized preproNPY peptide, we assessed the hypothesis that PreproNPY Leu7Pro polymorphism is a risk factor for type II diabetes, impaired glucose tolerance and hypertension. DESIGN: Blood pressure recordings and oral glucose tolerance test were performed in the hypertensive (n=515) and control cohorts (n=525) of our well-defined Oulu Project Elucidating Risk of Atherosclerosis (OPERA) study. The prevalence of type II diabetes was 9% (n=93). The genotypes, insulin and glucose metabolism indexes and plasma ghrelin of the subjects were determined. RESULTS: Pro7 allele frequencies were 5.9, 5.3 and 11.3% in the total cohort, in subjects without and with type II diabetes, respectively. The PreproNPY Pro7 carrier status was a significant risk factor for type II diabetes, and the effect remained significant after adjustment for age, sex, waist circumference and study group (odds ratio=3.02, confidence interval: 1.67-5.44 and P<0.001). Pro7 carriers were more insulin resistant and showed lower ghrelin levels compared to non-carriers. CONCLUSIONS: The PreproNPY Pro7 allele is associated with an increased risk for type II diabetes. The risk seems to be associated with a higher insulin resistance among Pro7 carriers whereas low ghrelin concentrations in Pro7 carriers are possibly a consequence of high insulin levels.
Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 2/genetics , Insulin/metabolism , Neuropeptide Y/genetics , Polymorphism, Genetic , Protein Precursors/genetics , Adult , Blood Pressure , Female , Gene Frequency , Genotype , Ghrelin/blood , Humans , Hypertension/genetics , Insulin/blood , Insulin Secretion , Leucine/genetics , Leucine/metabolism , Male , Middle Aged , Peptide Hormones/blood , Proline/genetics , Proline/metabolism , Risk FactorsABSTRACT
OBJECTIVE: Abdominal obesity, insulin resistance and compensatory hyperinsulinaemia play a central role in the pathogenesis of the polycystic ovary syndrome (PCOS). Abdominal adipose tissue is a source of adipokines, such as adiponectin and resistin, both of which may be involved in the development of insulin resistance and chronic inflammation in PCOS. Ghrelin, an important regulatory peptide of food intake, may also play a role in metabolic disturbances related to PCOS. The aim of this study was to examine the effects of 4 months of treatment with the insulin sensitizer rosiglitazone on plasma adiponectin, resistin and ghrelin levels in overweight women with PCOS. DESIGN: A randomised placebo-controlled study. METHODS: Thirty overweight/obese women with PCOS (body mass index>25 kg/m(2), mean age 29.1+/- 1.2 (S.E.M.) years) were randomly allocated to either rosiglitazone (Avandia, 4 mg twice a day) or placebo treatment. Plasma levels of adiponectin, resistin and ghrelin and their correlation to serum levels of insulin, C-peptide and steroid hormones, and insulin sensitivity (euglycaemic hyperinsulinaemic clamp) were assessed. RESULTS: Adiponectin and ghrelin levels correlated significantly with most metabolic markers of insulin resistance and with serum levels of DHEA and 17-hydroxyprogesterone. Plasma levels of adiponectin increased from 9.26+/-0.90 (S.E.M.) to 22.22+/-3.66 microg/ml (P<0.001) and those of resistin decreased from 12.57+/-1.63 to 9.21+/-0.53 ng/ml (P=0.009) at 4 months of treatment, but plasma ghrelin levels did not change. CONCLUSIONS: Rosiglitazone had beneficial effects on serum levels of adiponectin and resistin, suggesting that these adipocytokines may contribute to the improvement in insulin sensitivity observed during the treatment.
Subject(s)
Adiponectin/blood , Hypoglycemic Agents/administration & dosage , Polycystic Ovary Syndrome/drug therapy , Resistin/blood , Thiazolidinediones/administration & dosage , Adult , Female , Ghrelin , Humans , Hyperinsulinism/drug therapy , Hyperinsulinism/metabolism , Insulin Resistance , Peptide Hormones/blood , Placebos , Polycystic Ovary Syndrome/metabolism , RosiglitazoneABSTRACT
BACKGROUND: Ghrelin, a peptide hormone from stomach, stimulates food intake and decreases fat utilization. Ghrelin binds to growth hormone secretagogue receptor (GHSR). GHSR density has been shown to be upregulated in atherosclerotic lesions, but the relationship between ghrelin concentration and atherosclerosis has not yet been studied. We, therefore, characterized the association between ghrelin concentration and carotid artery intima-media thickness (IMT) in a population-based cohort of 1024 middle-aged (40-60 years) men and women. METHODS: Intima-media thickness and the number of atherosclerotic plaques were determined ultrasonographically. Fasting plasma ghrelin concentrations were analysed using RIA-kit (PhoenixPeptide). RESULTS: There was a positive association between mean IMT and ghrelin concentration in the analysis of males before and after adjustments for the traditional risk factors of atherosclerosis [age, systolic blood pressure, LDL cholesterol, body mass index (BMI), and smoking (ancova, P = 0.004 and P = 0.007, respectively)]. However, no such association was found in females (P = 0.985 and P = 0.915). There was no correlation between ghrelin and CRP concentrations or ghrelin and smoking. CONCLUSION: Ghrelin concentrations and carotid artery atherosclerosis are positively associated in males even after adjustment for the commonly recognized risk factors of atherosclerosis. Experimental and prospective studies are warranted to elucidate the role of ghrelin in atherosclerosis.